Spanish pharmaceutical company Almirall says it will change the production system used at its main manufacturing facility in Barcelona, in a bid to improve effeciency by 33%. The scheme, which was agreed with union representative prior to its announcement, is designed to generate productivity increments of around 10% a year, compared with 1%-2% achieved under the old system. The firm added that it would continue its program of internationalization by dedicating some 20% of its sales income over the next five years to R&D.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze